Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: Mr Vastag's Medical News & Perspectives article1 failed to present a balanced view regarding recruitment challenges for the Study of Tamoxifen and Raloxifene (STAR) trial and contained inaccurate and misleading information about raloxifene hydrochloride and Eli Lilly and Company.
Vastag correctly states that enrollment for STAR is nearly on target. Nevertheless, he reports study sites have faced challenges in meeting enrollment goals because physicians "have already decided that raloxifene is a better choice [than tamoxifen]." This claim is unsubstantiated and oversimplifies the complex dynamics of enrolling postmenopausal women in breast cancer trials.
Plouffe, Jr L. Raloxifene for Breast Cancer Prevention. JAMA. 2001;285(16):2079. doi:10.1001/jama.285.16.2079